| VARIABLE | FREQUENCY (%) |
| Initial management |
|
| Radiotherapy | 12 (5.91) |
| Gosereline | 42 (20.69) |
| Triptoreline | 21 (10.34) |
| Laparoscopic prostatectomy | 114 (56.16) |
| Pulpectomy | 11 (5.42) |
| Watchful waiting | 2 (0.99) |
| Surveillance | 1 (0.45) |
| Second treatment |
|
| Yes | 77 (37.93) |
| No | 126 (62.07) |
| Second treatment |
|
| Radiotherapy | 38 (49.35) |
| Decetaxel | 9 (11.69) |
| Abiraterone acetate | 20 (25.97) |
| Gosereline | 7 (9.1) |
| Triptoreline | 3 (3.90) |
| Third treatment |
|
| Yes | 24 (31.17) |
| No | 53 (68.83) |
| Third treatment |
|
| Decetaxel | 4 (16.67) |
| Abiraterone acetate | 1 (4.17) |
| Gosereline | 13 (54.17) |
| Triptoreline | 6 (25.00) |
| Final outcome |
|
| Survival | 170 (83.74) |
| Death | 33 (16.26) |
| Follow-up duration (Days) |
|
| ≤200 | 4 (1.97) |
| 201 - 700 | 53 (26.11) |
| 701 - 1200 | 82 (40.39) |
| 1201 - 1700 | 46 (22.66) |
| 1701 - 2000 | 11 (5.42) |
| >2000 | 7 (3.45) |